Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 56 entries
Sorted by: Best Match Show Resources per page
Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome.

Indian journal of nephrology

Raghunathan V, Sethi SK, Dragon-Durey MA, Dhaliwal M, Raina R, Jha P, Bansal SB, Kher V.
PMID: 28356668
Indian J Nephrol. 2017 Mar-Apr;27(2):136-140. doi: 10.4103/0971-4065.181462.

Hypertension is common in hemolytic uremic syndrome (HUS) and often difficult to control. Local renin-angiotensin activation is believed to be an important part of thrombotic microangiopathy, leading to a vicious cycle of progressive renal injury and intractable hypertension. This...

Cite
Raghunathan V, Sethi SK, Dragon-Durey MA, et al. Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome. Indian J Nephrol. 2017;27(2):136-140doi: 10.4103/0971-4065.181462.
Raghunathan, V., Sethi, S. K., Dragon-Durey, M. A., Dhaliwal, M., Raina, R., Jha, P., Bansal, S. B., & Kher, V. (2017). Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome. Indian journal of nephrology, 27(2), 136-140. https://doi.org/10.4103/0971-4065.181462
Raghunathan, V, et al. "Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome." Indian journal of nephrology vol. 27,2 (2017): 136-140. doi: https://doi.org/10.4103/0971-4065.181462
Raghunathan V, Sethi SK, Dragon-Durey MA, Dhaliwal M, Raina R, Jha P, Bansal SB, Kher V. Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome. Indian J Nephrol. 2017 Mar-Apr;27(2):136-140. doi: 10.4103/0971-4065.181462. PMID: 28356668; PMCID: PMC5358156.
Copy Download .nbib Format: NLM
Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): A randomized, two-way, open-label, crossover study in healthy volunteers.

Current therapeutic research, clinical and experimental

Portolés A, Terleira A, Almeida S, García-Arenillas M, Caturla MC, Filipe A, Vargas E.
PMID: 24936102
Curr Ther Res Clin Exp. 2004 Jan;65(1):34-46. doi: 10.1016/S0011-393X(04)90003-3.

BACKGROUND: Enalapril maleate is the monoethyl ester prodrug of enalapril- at, an angiotensin-converting enzyme inhibitor indicated in the management of essential and renovascular hypertension, and in the treatment of congestive heart failure and in asymptomatic patients with left ventricular...

Cite
Portolés A, Terleira A, Almeida S, et al. Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): A randomized, two-way, open-label, crossover study in healthy volunteers. Curr Ther Res Clin Exp. 2004;65(1):34-46doi: 10.1016/S0011-393X(04)90003-3.
Portolés, A., Terleira, A., Almeida, S., García-Arenillas, M., Caturla, M. C., Filipe, A., & Vargas, E. (2004). Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): A randomized, two-way, open-label, crossover study in healthy volunteers. Current therapeutic research, clinical and experimental, 65(1), 34-46. https://doi.org/10.1016/S0011-393X(04)90003-3
Portolés, Antonio, et al. "Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): A randomized, two-way, open-label, crossover study in healthy volunteers." Current therapeutic research, clinical and experimental vol. 65,1 (2004): 34-46. doi: https://doi.org/10.1016/S0011-393X(04)90003-3
Portolés A, Terleira A, Almeida S, García-Arenillas M, Caturla MC, Filipe A, Vargas E. Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): A randomized, two-way, open-label, crossover study in healthy volunteers. Curr Ther Res Clin Exp. 2004 Jan;65(1):34-46. doi: 10.1016/S0011-393X(04)90003-3. PMID: 24936102; PMCID: PMC4052970.
Copy Download .nbib Format: NLM
A Liquid Chromatography-Tandem Mass Spectrometry Method for Evaluation of Two Brands of Enalapril 20 mg Tablets in Healthy Human Volunteers.

Journal of analytical methods in chemistry

Dayyih WA, Hamad M, Awwad AA, Mallah E, Zakarya Z, Dayyih AA, Arafat T.
PMID: 28894622
J Anal Methods Chem. 2017;2017:8489471. doi: 10.1155/2017/8489471. Epub 2017 Aug 15.

Enalapril is an angiotensin-converting enzyme inhibitor used for treatment of hypertension and chronic heart disease. Enalaprilat is its active metabolite responsible for the activity. This study aimed to develop and validate a method for enalapril and enalaprilat analysis and...

Cite
Dayyih WA, Hamad M, Awwad AA, et al. A Liquid Chromatography-Tandem Mass Spectrometry Method for Evaluation of Two Brands of Enalapril 20 mg Tablets in Healthy Human Volunteers. J Anal Methods Chem. 2017;2017:8489471doi: 10.1155/2017/8489471.
Dayyih, W. A., Hamad, M., Awwad, A. A., Mallah, E., Zakarya, Z., Dayyih, A. A., & Arafat, T. (2017). A Liquid Chromatography-Tandem Mass Spectrometry Method for Evaluation of Two Brands of Enalapril 20 mg Tablets in Healthy Human Volunteers. Journal of analytical methods in chemistry, 20178489471. https://doi.org/10.1155/2017/8489471
Dayyih, Wael Abu, et al. "A Liquid Chromatography-Tandem Mass Spectrometry Method for Evaluation of Two Brands of Enalapril 20 mg Tablets in Healthy Human Volunteers." Journal of analytical methods in chemistry vol. 2017 (2017): 8489471. doi: https://doi.org/10.1155/2017/8489471
Dayyih WA, Hamad M, Awwad AA, Mallah E, Zakarya Z, Dayyih AA, Arafat T. A Liquid Chromatography-Tandem Mass Spectrometry Method for Evaluation of Two Brands of Enalapril 20 mg Tablets in Healthy Human Volunteers. J Anal Methods Chem. 2017;2017:8489471. doi: 10.1155/2017/8489471. Epub 2017 Aug 15. PMID: 28894622; PMCID: PMC5574226.
Copy Download .nbib Format: NLM
In Vivo Effects of Bradykinin B2 Receptor Agonists with Varying Susceptibility to Peptidases.

Frontiers in pharmacology

Jean M, Gera L, Charest-Morin X, Marceau F, Bachelard H.
PMID: 26793104
Front Pharmacol. 2016 Jan 12;6:306. doi: 10.3389/fphar.2015.00306. eCollection 2015.

We reported evidence of bradykinin (BK) regeneration from C-terminal extended BK sequences that behave as peptidase-activated B2 receptor (B2R) agonists. Further to these in vitro studies, we carried out in vivo experiments to verify hemodynamic effects of BK analogs...

Cite
Jean M, Gera L, Charest-Morin X, et al. In Vivo Effects of Bradykinin B2 Receptor Agonists with Varying Susceptibility to Peptidases. Front Pharmacol. 2016;6:306doi: 10.3389/fphar.2015.00306.
Jean, M., Gera, L., Charest-Morin, X., Marceau, F., & Bachelard, H. (2015). In Vivo Effects of Bradykinin B2 Receptor Agonists with Varying Susceptibility to Peptidases. Frontiers in pharmacology, 6306. https://doi.org/10.3389/fphar.2015.00306
Jean, Mélissa, et al. "In Vivo Effects of Bradykinin B2 Receptor Agonists with Varying Susceptibility to Peptidases." Frontiers in pharmacology vol. 6 (2015): 306. doi: https://doi.org/10.3389/fphar.2015.00306
Jean M, Gera L, Charest-Morin X, Marceau F, Bachelard H. In Vivo Effects of Bradykinin B2 Receptor Agonists with Varying Susceptibility to Peptidases. Front Pharmacol. 2016 Jan 12;6:306. doi: 10.3389/fphar.2015.00306. eCollection 2015. PMID: 26793104; PMCID: PMC4709452.
Copy Download .nbib Format: NLM
An optimized fluoroenzymatic assay for the determination of angiotensin converting enzyme inhibitors in biological fluids.

Journal of pharmaceutical and biomedical analysis

Shepley K, Rocci ML, Patrick H, Mojaverian P.
PMID: 16867414
J Pharm Biomed Anal. 1988;6(3):241-51. doi: 10.1016/0731-7085(88)80050-5.

An easy, analytically sound fluoroenzymatic assay for angiotensin converting enzyme (ACE) inhibitors is described. Drug samples and standards are extracted with methanol and evaporated to dryness. Drug residues are then incubated with the substrate N-benzyloxycarbonyl-phenyllanyl-l-histidyl-leucine and human plasma ACE...

Cite
Shepley K, Rocci ML, Patrick H, et al. An optimized fluoroenzymatic assay for the determination of angiotensin converting enzyme inhibitors in biological fluids. J Pharm Biomed Anal. 1988;6(3):241-51doi: 10.1016/0731-7085(88)80050-5.
Shepley, K., Rocci, M. L., Patrick, H., & Mojaverian, P. (1988). An optimized fluoroenzymatic assay for the determination of angiotensin converting enzyme inhibitors in biological fluids. Journal of pharmaceutical and biomedical analysis, 6(3), 241-51. https://doi.org/10.1016/0731-7085(88)80050-5
Shepley, K, et al. "An optimized fluoroenzymatic assay for the determination of angiotensin converting enzyme inhibitors in biological fluids." Journal of pharmaceutical and biomedical analysis vol. 6,3 (1988): 241-51. doi: https://doi.org/10.1016/0731-7085(88)80050-5
Shepley K, Rocci ML, Patrick H, Mojaverian P. An optimized fluoroenzymatic assay for the determination of angiotensin converting enzyme inhibitors in biological fluids. J Pharm Biomed Anal. 1988;6(3):241-51. doi: 10.1016/0731-7085(88)80050-5. PMID: 16867414.
Copy Download .nbib Format: NLM
The brain Renin-Angiotensin system and the regulation of prolactin secretion in female rats: influence of ovarian hormones.

Journal of neuroendocrinology

Myers LS, Steele MK.
PMID: 19210444
J Neuroendocrinol. 1989 Aug 01;1(4):299-303. doi: 10.1111/j.1365-2826.1989.tb00119.x.

Abstract This study was designed to investigate the effects of exogenous and endogenous angiotensin II (All) on prolactin release in ovariectomized rats, with and without estrogen and progesterone pretreatment. In the first series of experiments, All or vehicle was...

Cite
Myers LS, Steele MK. The brain Renin-Angiotensin system and the regulation of prolactin secretion in female rats: influence of ovarian hormones. J Neuroendocrinol. 1989;1(4):299-303doi: 10.1111/j.1365-2826.1989.tb00119.x.
Myers, L. S., & Steele, M. K. (1989). The brain Renin-Angiotensin system and the regulation of prolactin secretion in female rats: influence of ovarian hormones. Journal of neuroendocrinology, 1(4), 299-303. https://doi.org/10.1111/j.1365-2826.1989.tb00119.x
Myers, L S, and Steele, M K. "The brain Renin-Angiotensin system and the regulation of prolactin secretion in female rats: influence of ovarian hormones." Journal of neuroendocrinology vol. 1,4 (1989): 299-303. doi: https://doi.org/10.1111/j.1365-2826.1989.tb00119.x
Myers LS, Steele MK. The brain Renin-Angiotensin system and the regulation of prolactin secretion in female rats: influence of ovarian hormones. J Neuroendocrinol. 1989 Aug 01;1(4):299-303. doi: 10.1111/j.1365-2826.1989.tb00119.x. PMID: 19210444.
Copy Download .nbib Format: NLM
Analysis of responses to angiotensin II in the mouse.

Journal of the renin-angiotensin-aldosterone system : JRAAS

Bivalacqua TJ, Champion HC, Hyman AL, McNamara DB, Kadowitz PJ.
PMID: 28095236
J Renin Angiotensin Aldosterone Syst. 2001 Mar;2(1):S48-S53. doi: 10.1177/14703203010020010801.

Responses to angiotensin II (Ang II) were investigated in anaesthetised CD1 mice. Injections of Ang II caused dose-related increases in systemic arterial pressure that were antagonised by candesartan. Responses to Ang II were not altered by PD 123319. At...

Cite
Bivalacqua TJ, Champion HC, Hyman AL, et al. Analysis of responses to angiotensin II in the mouse. J Renin Angiotensin Aldosterone Syst. 2001;2(1):S48-S53doi: 10.1177/14703203010020010801.
Bivalacqua, T. J., Champion, H. C., Hyman, A. L., McNamara, D. B., & Kadowitz, P. J. (2001). Analysis of responses to angiotensin II in the mouse. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2(1), S48-S53. https://doi.org/10.1177/14703203010020010801
Bivalacqua, Trinity J, et al. "Analysis of responses to angiotensin II in the mouse." Journal of the renin-angiotensin-aldosterone system : JRAAS vol. 2,1 (2001): S48-S53. doi: https://doi.org/10.1177/14703203010020010801
Bivalacqua TJ, Champion HC, Hyman AL, McNamara DB, Kadowitz PJ. Analysis of responses to angiotensin II in the mouse. J Renin Angiotensin Aldosterone Syst. 2001 Mar;2(1):S48-S53. doi: 10.1177/14703203010020010801. PMID: 28095236.
Copy Download .nbib Format: NLM
Pharmacokinetics and drug-drug interaction between enalapril, enalaprilat and felodipine extended release (ER) in healthy subjects.

Oncotarget

Li D, Xu S, Wang Y, Li D, Li X, Pan J, Xu P.
PMID: 29050316
Oncotarget. 2017 Aug 07;8(41):70752-70760. doi: 10.18632/oncotarget.19984. eCollection 2017 Sep 19.

Since angiotensin-converting enzyme (ACE) inhibitors and calcium antagonists have complimentary mechanisms of action, enalapril, an ACE inhibitor, is used in combination with felodipine, a vascular selective dihydropyridine calcium antagonist, for the treatment of hypertension. The present study was designed...

Cite
Li D, Xu S, Wang Y, et al. Pharmacokinetics and drug-drug interaction between enalapril, enalaprilat and felodipine extended release (ER) in healthy subjects. Oncotarget. 2017;8(41):70752-70760doi: 10.18632/oncotarget.19984.
Li, D., Xu, S., Wang, Y., Li, D., Li, X., Pan, J., & Xu, P. (2017). Pharmacokinetics and drug-drug interaction between enalapril, enalaprilat and felodipine extended release (ER) in healthy subjects. Oncotarget, 8(41), 70752-70760. https://doi.org/10.18632/oncotarget.19984
Li, Dai, et al. "Pharmacokinetics and drug-drug interaction between enalapril, enalaprilat and felodipine extended release (ER) in healthy subjects." Oncotarget vol. 8,41 (2017): 70752-70760. doi: https://doi.org/10.18632/oncotarget.19984
Li D, Xu S, Wang Y, Li D, Li X, Pan J, Xu P. Pharmacokinetics and drug-drug interaction between enalapril, enalaprilat and felodipine extended release (ER) in healthy subjects. Oncotarget. 2017 Aug 07;8(41):70752-70760. doi: 10.18632/oncotarget.19984. eCollection 2017 Sep 19. PMID: 29050316; PMCID: PMC5642591.
Copy Download .nbib Format: NLM
Tailored Assays for Pharmacokinetic and Pharmacodynamic Investigations of Aliskiren and Enalapril in Children: An Application in Serum, Urine, and Saliva.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG

Burckhardt BB, Tins J, Ramusovic S, Läer S.
PMID: 26766933
J Pediatr Pharmacol Ther. 2015 Nov-Dec;20(6):431-52. doi: 10.5863/1551-6776-20.6.431.

OBJECTIVES: Drugs that are effectively used to treat hypertension in adults (e.g., enalapril) have not been sufficiently investigated in children. Studies required for pediatric approval require special consideration regarding ethics, study design, and conduct and are also associated with...

Cite
Burckhardt BB, Tins J, Ramusovic S, et al. Tailored Assays for Pharmacokinetic and Pharmacodynamic Investigations of Aliskiren and Enalapril in Children: An Application in Serum, Urine, and Saliva. J Pediatr Pharmacol Ther. 2015;20(6):431-52doi: 10.5863/1551-6776-20.6.431.
Burckhardt, B. B., Tins, J., Ramusovic, S., & Läer, S. (2015). Tailored Assays for Pharmacokinetic and Pharmacodynamic Investigations of Aliskiren and Enalapril in Children: An Application in Serum, Urine, and Saliva. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 20(6), 431-52. https://doi.org/10.5863/1551-6776-20.6.431
Burckhardt, Bjoern B, et al. "Tailored Assays for Pharmacokinetic and Pharmacodynamic Investigations of Aliskiren and Enalapril in Children: An Application in Serum, Urine, and Saliva." The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG vol. 20,6 (2015): 431-52. doi: https://doi.org/10.5863/1551-6776-20.6.431
Burckhardt BB, Tins J, Ramusovic S, Läer S. Tailored Assays for Pharmacokinetic and Pharmacodynamic Investigations of Aliskiren and Enalapril in Children: An Application in Serum, Urine, and Saliva. J Pediatr Pharmacol Ther. 2015 Nov-Dec;20(6):431-52. doi: 10.5863/1551-6776-20.6.431. PMID: 26766933; PMCID: PMC4708953.
Copy Download .nbib Format: NLM
Urine N-acetyl-Ser-Asp-Lys-Pro measurement as a versatile biomarker to assess adherence to angiotensin-converting enzyme inhibitors.

Journal of hypertension

Kably B, Billaud EM, Derobertmasure A, Blanchard A, Boutouyrie P, Azizi M.
PMID: 34508023
J Hypertens. 2022 Feb 01;40(2):348-355. doi: 10.1097/HJH.0000000000003018.

BACKGROUND: Poor adherence to treatment is a major health issue in hypertension. The large number of drugs to be detected limits the implementation of chemical adherence testing by liquid chromatography/mass spectrometry (LC-MS/MS). AcSDKP, a peptide accumulating in the presence...

Cite
Kably B, Billaud EM, Derobertmasure A, et al. Urine N-acetyl-Ser-Asp-Lys-Pro measurement as a versatile biomarker to assess adherence to angiotensin-converting enzyme inhibitors. J Hypertens. 2022;40(2):348-355doi: 10.1097/HJH.0000000000003018.
Kably, B., Billaud, E. M., Derobertmasure, A., Blanchard, A., Boutouyrie, P., & Azizi, M. (2022). Urine N-acetyl-Ser-Asp-Lys-Pro measurement as a versatile biomarker to assess adherence to angiotensin-converting enzyme inhibitors. Journal of hypertension, 40(2), 348-355. https://doi.org/10.1097/HJH.0000000000003018
Kably, Benjamin, et al. "Urine N-acetyl-Ser-Asp-Lys-Pro measurement as a versatile biomarker to assess adherence to angiotensin-converting enzyme inhibitors." Journal of hypertension vol. 40,2 (2022): 348-355. doi: https://doi.org/10.1097/HJH.0000000000003018
Kably B, Billaud EM, Derobertmasure A, Blanchard A, Boutouyrie P, Azizi M. Urine N-acetyl-Ser-Asp-Lys-Pro measurement as a versatile biomarker to assess adherence to angiotensin-converting enzyme inhibitors. J Hypertens. 2022 Feb 01;40(2):348-355. doi: 10.1097/HJH.0000000000003018. PMID: 34508023.
Copy Download .nbib Format: NLM
Pharmacology of enalapril in children: a review.

Drug discovery today

Smeets NJL, Schreuder MF, Dalinghaus M, Male C, Lagler FB, Walsh J, Laer S, de Wildt SN.
PMID: 32835726
Drug Discov Today. 2020 Aug 21; doi: 10.1016/j.drudis.2020.08.005. Epub 2020 Aug 21.

Enalapril is an angiotensin-converting enzyme (ACE) inhibitor that is used for the treatment of (paediatric) hypertension, heart failure and chronic kidney diseases. Because its disposition, efficacy and safety differs across the paediatric continuum, data from adults cannot be automatically...

Cite
Smeets NJL, Schreuder MF, Dalinghaus M, et al. Pharmacology of enalapril in children: a review. Drug Discov Today. 2020;doi: 10.1016/j.drudis.2020.08.005.
Smeets, N. J. L., Schreuder, M. F., Dalinghaus, M., Male, C., Lagler, F. B., Walsh, J., Laer, S., & de Wildt, S. N. (2020). Pharmacology of enalapril in children: a review. Drug discovery today, . https://doi.org/10.1016/j.drudis.2020.08.005
Smeets, Nori J L, et al. "Pharmacology of enalapril in children: a review." Drug discovery today vol. (2020). doi: https://doi.org/10.1016/j.drudis.2020.08.005
Smeets NJL, Schreuder MF, Dalinghaus M, Male C, Lagler FB, Walsh J, Laer S, de Wildt SN. Pharmacology of enalapril in children: a review. Drug Discov Today. 2020 Aug 21; doi: 10.1016/j.drudis.2020.08.005. Epub 2020 Aug 21. PMID: 32835726.
Copy Download .nbib Format: NLM
Orodispersible minitablets of enalapril for use in children with heart failure (LENA): Rationale and protocol for a multicentre pharmacokinetic bridging study and follow-up safety study.

Contemporary clinical trials communications

Bajcetic M, de Wildt SN, Dalinghaus M, Breitkreutz J, Klingmann I, Lagler FB, Keatley-Clarke A, Breur JM, Male C, Jovanovic I, Szatmári A, Ablonczy L, Burckhardt BB, Cawello W, Kleine K, Obarcanin E, Spatenkova L, Swoboda V, van der Meulen M, Wagner P, Walsh J, Läer S.
PMID: 31249901
Contemp Clin Trials Commun. 2019 Jun 08;15:100393. doi: 10.1016/j.conctc.2019.100393. eCollection 2019 Sep.

INTRODUCTION: Treatment of paediatric heart failure is based on paradigms extensively tested in the adult population assuming similar underlying pathophysiological mechanisms. Angiotensin converting enzyme inhibitors (ACEI) like enalapril are one of the cornerstones of treatment and commonly used off-label...

Cite
Bajcetic M, de Wildt SN, Dalinghaus M, et al. Orodispersible minitablets of enalapril for use in children with heart failure (LENA): Rationale and protocol for a multicentre pharmacokinetic bridging study and follow-up safety study. Contemp Clin Trials Commun. 2019;15:100393doi: 10.1016/j.conctc.2019.100393.
Bajcetic, M., de Wildt, S. N., Dalinghaus, M., Breitkreutz, J., Klingmann, I., Lagler, F. B., Keatley-Clarke, A., Breur, J. M., Male, C., Jovanovic, I., Szatmári, A., Ablonczy, L., Burckhardt, B. B., Cawello, W., Kleine, K., Obarcanin, E., Spatenkova, L., Swoboda, V., van der Meulen, M., Wagner, P., Walsh, J., & Läer, S. (2019). Orodispersible minitablets of enalapril for use in children with heart failure (LENA): Rationale and protocol for a multicentre pharmacokinetic bridging study and follow-up safety study. Contemporary clinical trials communications, 15100393. https://doi.org/10.1016/j.conctc.2019.100393
Bajcetic, Milica, et al. "Orodispersible minitablets of enalapril for use in children with heart failure (LENA): Rationale and protocol for a multicentre pharmacokinetic bridging study and follow-up safety study." Contemporary clinical trials communications vol. 15 (2019): 100393. doi: https://doi.org/10.1016/j.conctc.2019.100393
Bajcetic M, de Wildt SN, Dalinghaus M, Breitkreutz J, Klingmann I, Lagler FB, Keatley-Clarke A, Breur JM, Male C, Jovanovic I, Szatmári A, Ablonczy L, Burckhardt BB, Cawello W, Kleine K, Obarcanin E, Spatenkova L, Swoboda V, van der Meulen M, Wagner P, Walsh J, Läer S. Orodispersible minitablets of enalapril for use in children with heart failure (LENA): Rationale and protocol for a multicentre pharmacokinetic bridging study and follow-up safety study. Contemp Clin Trials Commun. 2019 Jun 08;15:100393. doi: 10.1016/j.conctc.2019.100393. eCollection 2019 Sep. PMID: 31249901; PMCID: PMC6586986.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 56 entries